生物活性 | |||
---|---|---|---|
描述 | GANT61 (20 μM) induces more significant cell death compared to targeting Smo (cyclopamine). It also inhibits the clonogenic survival of human colon carcinoma cell lines (0, 5, 10, 20 μM). Moreover, GANT61 (20 μM, 0-72 hr) downregulates Gli1 and Gli2 expression in HT29 cells. Additionally, GANT61 (0, 10 μM, or 20 μM) differentially regulates genes involved in the balance between cell death and survival[1]. GANT-61 inhibits cell viability and induces apoptosis in pancreatic CSCs. It also suppresses the expression of downstream targets of the Shh pathway, decreases Gli-DNA interaction, Gli transcriptional activity, and Gli nuclear translocation in pancreatic CSCs. Furthermore, GANT-61 modulates genes associated with cell survival, cell death, and pluripotency, while also inhibiting the motility, invasion, and migration of CSCs[2]. The sensitivity of GANT61 correlates positively with GLI1 and negatively with MYCN expression in the tested neuroblastoma cell lines. GANT61 downregulates the expression of GLI1, c-MYC, MYCN, and Cyclin D1, and induces apoptosis in neuroblastoma cells[3]. |
细胞研究 | |||||
---|---|---|---|---|---|
细胞系 | 浓度 | 检测类型 | 检测时间 | 活性说明 | 数据源 |
HEK293 cells | Function assay | Reduction of GLI2 mediated transcription in HEK293 cells by luciferase reporter assay | 17494766 | ||
HEK293 cells | Function assay | Inhibition of beta galactosidase in HEK293 cells | 17494766 | ||
human 22Rv cells | Function assay | Reduction of expression of PTCH mRNA in human 22Rv cells | 17494766 |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.33mL 0.47mL 0.23mL |
11.64mL 2.33mL 1.16mL |
23.28mL 4.66mL 2.33mL |
参考文献 |
---|